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sue culture cabinet in a grade B clean room environment monitored for
particulate and microbiological contamination during cell processing in
accordance with Rules and Guidance for Pharmaceutical Manufacturers
and Distributors — The Orange Guide, compiled by the UK Medicines
Healthcare Products Regulatory Authority (go to: https://www.gov.
uk/guidance/good-manufacturing-practice-and-good-distribution-
practice). Accordingly, the facility was operating under a mature Qual-
ity Management System, compliant with ISO9001:2008 standards.
HESC derivation was performed under licensure from the UK HFEA
(R0136 to centre 0202) and HTA (Licensing Number 22631).
HESC derivation involved whole embryo outgrowth on mitotically
inactivated human dermal ﬁbroblast (HDF) feeder cells. HDFs were de-
rived and manufactured according to GMP and had been approved for
clinical use by the Food and Drug Administration, USA. During deriva-
tion on HDFs, hESCs were grown in a xeno-free cell therapy grade
media (XF KODMEM) supplemented with xeno-free human recombi-
nant bFGF. The cell line was subsequently expanded in a GMP grade
serum-free medium (StemPro hESC Serum Free Medium) on a xeno-
free matrix (CellStart). The former contained bovine serum albumin
(BSA) from a Transmissible Spongiform Encephalopathy (TSE)-free
country of origin. The cell line was cryopreserved in a GMP compliant
cryopreservation solution (CryoStor CS10).
By ﬂow cytometry, RCe021-A (RC-17) expressed the pluripotency
makers Oct-4, Tra-1-60 and SSEA-4 (89.8%, 70.8% and 94.7%, respective-
ly), whereas lower expression of the differentiation marker SSEA-1
(10.2%)was observed (Figs. 1, 2). Differentiation to the three germ layers,
endoderm, ectoderm and mesoderm, was demonstrated using embryoid
body formation in vitro, and expression of the germ layer markers
α-fetoprotein, β-tubulin and muscle actin was observed (Fig. 3).Fig. 1. Quality Control Certiﬁcate of AnalysiA microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 1). Blood group genotyping
gave the blood group O1O1, expected to give rise to blood group O+
(Table 1). The cell line is free frommycoplasma contamination as deter-
mined by RT-qPCR.Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding and
showed a normal 46XX female genotype (Fig. 4). SNP genotyping was
carried out using the IlluminaHumanCytoSNP-12 v2.1 BeadChip and re-
vealed a 144 kb gain on chromosome12p13.31 as described in Canham
et al. 2015. This region contains the genes, SLC2A14; SLC2A3. Duplica-
tions and deletions of this region are found commonly in healthy indi-
viduals (1 n 25) as documented by the Database of Genomic Variants
(MacDonald et al. 2014).Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland A Research
Ethics Committee and local ethics board at participating fertility clinics
and conducted under licence no R0136 from the UK HFEA with in-
formed donor consent. The processing and storage of hESC cells for
human application were conducted under licence number 22631 from
the UK Human Tissue Authority.s for RC-17 (RCe021-A) P12A seed lot.
Fig. 2. RCe021-A (RC-17) was subjected to ﬂow cytometry analysis for markers of pluripotency with speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the
histograms. Percentage staining is indicated in the Certiﬁcate of Analysis (CoA, Fig. 1).
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Fresh embryos were cultured in Sydney cleavage medium (Cook
Medical, Hertfordshire, UK) until day 3 and Sydney blastocyst medium
(CookMedical) after day 3 of development.Mediumwas supplemented
with 2 ng/ml Granulocyte-Macrophage Colony-Stimulating Factor (GM-
CSF, Miltenyi Biotech, Bisley, UK). Embryos were cultured at 36.5–
37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 in drops under parafﬁn oil
(CookMedical) and transferred to freshmedium at least every 2–3 days.
By day 8 of development, embryos were placed in derivation condi-
tions consisting of mitotically inactivated GMP grade neonatal human
dermal ﬁbroblasts (HDFs) (Forticell Biosciences, NJ, USA) on tissue cul-
ture plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF,
2 mM L-glutamine, 1% MEM non-essential amino acids, 2% XF Growth
Factor Cocktail, 0.1 mM β-mercaptoethanol (Thermo Fisher Scientiﬁc,
Paisley, UK) supplemented with 80 ng/ml human bFGF (Thermo Fisher
Scientiﬁc). When available, cell therapy system quality reagents were
used. Assisted hatchingwas performed by removing the zonapellucidae
mechanically using Swemed cutting tools (Vitrolife, Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma
grade FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-
glutamine (Thermo Fisher Scientiﬁc). HDF were mitotically inactivated
using gamma irradiation at 50 Gy using a Gammacell Elite 1000 ma-
chine. For use as a feeder layer, irradiated HDFs were plated at
50,000 cells/cm2 in XF KODMEM medium supplemented with
80 ng/ml human bFGF (Thermo Fisher Scientiﬁc). Cells were cultured
at 36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 and 50% medium ex-
changed 6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (cell therapy system
quality reagents, Thermo Fisher Scientiﬁc). This contained BSA from a
TSE-free country of origin. Passaging was performed mechanically
using an EZ passage tool (Thermo Fisher Scientiﬁc). hESC lines were ex-
panded to 25–30 wells of a 6-well plate and cryopreserved in 0.5–1 mlFig. 3. In vitro differentiation of RCe021-A (RC-17) to ectoderm (β-tubulin III), mesoderm (mus
counterstained with DAPI (blue).Cryostor CS10 (Biolife Solution, Washington, USA) using an EF600-107
controlled rate freezer (Grant Instruments, Cambridge, UK) before
being stored in a −150 °C freezer (Panasonic Biomedical, Loughbor-
ough, UK).
Mycoplasma
In process mycoplasma detection was performed using Applied
Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and
MicroSEQ™MycoplasmaReal-TimePCRDetectionKit (ThermoFisher Sci-
entiﬁc (Applied Biosystems)) according to themanufacturer's instruction.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
the manufacturer's instructions. Brieﬂy, an unknown sample was com-
pared with a standard curve of known levels of control endotoxin. An
assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and
the CV (%) for the standard curve was ≤10%, and the reaction time of
the negative control was greater than the reaction time of the lowest
standard on the standard curve.
Flow cytometry
Pluripotency was determined using the Human andMouse Pluripo-
tent Stem Cell Analysis Kit (BD, Oxford, UK). Oct 3/4 and SSEA-4 were
included as pluripotencymarkers, and SSEA-1 as a differentiationmark-
er. FITC conjugated Tra-1-60 (BD) was used as an additional
pluripotency marker. Fixed and permeabilised cells were analysed
using a FACS Aria ﬂow cytometer (BD) or a Guava easyCyte ﬂow
cytometer (Millipore, Watford, UK). Percentage expression of each
marker was compared to isotype control or unstained cells.cle Actin), and endoderm (α-fetoprotein). Speciﬁc staining shown in green, cell nuclei are
Table 1
Microsatellite PCR, blood group and HLA tissue typing results for RCe021-A (RC-17).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2 D16S539 1 D16S539 2 D2S1338 1 D2S1338 2
15 18 17 18 11 11 21 23
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2 D21S11 1 D21S11 2 D18S51 1 D18S51 2
X X 10 12 28 29 12 15
D19S433 1 D19S433 2 THO1 1 THO1 2 FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
12 14 7 9 20 20 11 12
D5S818 1 D5S818 2 D7S820 1 D7S820 2 D13S317 1 D13S317 2 TPOX 1 TPOX 2
11 12 9 10 8 12 9 12
Blood group genotyping
RhD RhC Rhc RhE Rhe Fy a Fy b Fy GATA
pos pos pos pos pos pos neg neg
Jka Jkb K k M N S s
neg pos neg pos pos pos neg pos
Do a Do b ABO
pos pos O1O1
HLA tissue typing
HLA Class I Type HLA-A*01, A*03; B*07, B*08; C*07
HLA Class II Type HLA-DRB1*03, DRB1*11; DRB3*01; DQB1*02, DQB1*03
Comment DRB1*03 is expressed serologically as DR17, DQB1*03 is expressed serologically as DQ7.
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Viability was determined using the Guava ViaCount assay. Brieﬂy,
the Guava Viacount reagent (Millipore) containing a nuclear and aFig. 4. RCe021-A (RC-17) was analysed by Giemsa staining of 30 metaphase sprviability dye, was mixed with a single cell suspension, incubated for
5 min and analysed using the Guava easyCyte ﬂow cytometer
(Millipore). Total cell count, viable cell count and percentage viable
cells was obtained.eads and showed a normal 46XX female karyotype all 30 spreads analysed.
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hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (Thermo Fisher Scientiﬁc) and embryoid bodies
(EBs) generated in ultra low attachment plates (Corning) for 7 days be-
fore being transferred into EBmedium (20% FBS (GE Healthcare (PAA)),
80% KO-DMEM 1 mM L-glutamine, 3.5 μM β-mercaptoethanol, 1% non-
essential amino acids (all Thermo Fisher Scientiﬁc)), on glass slide tissue
culture chambers (Nunc, Thermo Fisher Scientiﬁc) coatedwith 0.2% gel-
atin (Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for 14 days.Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (Thermo Fisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (Thermo Fisher Scien-
tiﬁc) and stainedwith AFP (1:500; Sigma),β-tubulin III (1:1000; Sigma)
and muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark) and sec-
ondary antibody antimouse IgG-AlexaFluor 488 (1:200; Sigma). Images
were acquired using a Zeiss S100 Axiovert ﬂuorescence microscope or
Nikon eC1 confocal microscope.SNP genotyping and analysis
DNA samples were assayed using the Illumina HumanCytoSNP-12
v2.1 BeadChip. Genotyping data was initially assessed using
GenomeStudio genotyping module (v1.94, Illumina). Karyostudio
(v1.4, Illumina) was employed to perform automatic normalisation
and to identify genomic aberrations utilising default settings of the
built-in cnvPartition algorithm (3.07, Illumina) to generate B-allele fre-
quency and smoothened Log R ratio plots for detected regions. These
parameters are designed to detect CNVs greater than 75 kb and CN-
LOH regions larger than 1 MB with a conﬁdence value greater than 35.
All identiﬁed regions were ﬁrst cross-matched to the Database of Geno-
mic Variants (DGV; http://dgv.tcag.ca) to identify naturally-occurring
structural variations in the human. CNVs that were not identiﬁed on
the DGV were then checked against a list of ES cell-associated culture
adaptation genomic variants published by the International Stem Cell
Initiative (Amps et al. 2011). See also Canham et al. 2015 for further
details.Genomic analysis and outsourced assays
All outsourced assayswere carried out under aQuality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini Kit
(Qiagen, Manchester, UK) according to manufacturer's recommenda-
tions and provided in recommended quantities to the service providers.
Microsatellite PCR, or Short TandemRepeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A proﬁle was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnos-
tics laboratory at NHSBT.
Karyotype analysis was carried out by the Western General Cytoge-
netics Laboratory (Edinburgh, UK). Live cells at 60–70% conﬂuencywere
shipped in warm containers, ﬁxed and analysed by standard G-banding
analysis. For clinical grade lines, 30 spreads were analysed.
Viral screening for cytomegalovirus (CMV), Human T-cell
lymphotropic virus (HTLV)-1, Human immunodeﬁciency virus (HIV)-
1, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Epstein–Barr
virus (EBV) was carried out by The Doctors Laboratory (London, UK).
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